PTC Therapeutics Q3 revenue $196.8M, raises FY2024 guidance to $750-800M, multiple FDA submissions

PTC THERAPEUTICS, INC.

2024-Q3 EPS reported -$3.88 revenue$593,608,000

Q3 total revenue $196.8M (vs $196.6M YoY); DMD franchise $124M (Translarna $72M, Emflaza $52M).
Net loss narrowed to $106.7M from $133M; cash & securities $1.01B.
FY2024 revenue guidance raised to $750-800M; GAAP R&D+SG&A $740-835M.
FDA accepted sepiapterin NDA (PKU) with action date July 29, 2025; AADC gene therapy BLA action Nov 13, 2024.
Plans to submit vatiquinone NDA for Friedreich ataxia in Dec 2024; fast track for PTC518 Huntington's.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.